Dabomb Protein Biotech Corporation

Dabomb Protein Biotech Corporation

TTPEX:6578
15.90
TWD
-0.10
(-0.62%)
-0.35EPS
1.18BMarket Cap

Total Valuation

TWD

As of September 30, 2026, Dabomb Protein Biotech Corporation carries a market capitalization of 1.18B, placing it among publicly traded companies globally. Its enterprise value stands at 1.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.18B
Enterprise Value1.08B

Share Statistics

As of September 30, 2026, Dabomb Protein Biotech Corporation has 71.94M shares outstanding.

Shares Outstanding71.94M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.13, and the price-to-book ratio stands at 1.17.

PS Ratio3.13
PB Ratio1.17
P/TBV Ratio1.17
P/FCF Ratio66.51
P/OCF Ratio37.25

Enterprise Valuation

As of September 30, 2026, Dabomb Protein Biotech Corporation trades at an EV/EBITDA multiple of 32.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 244.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.08B versus a market cap of 1.18B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.87
EV / EBITDA32.50
EV / EBIT244.72

Financial Position

As of September 30, 2026, Dabomb Protein Biotech Corporation maintains a current ratio of 2.03, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.66, indicating elevated leverage, while an interest coverage ratio of 18.39 demonstrates strong ability to service its debt obligations.

Current Ratio2.03
Quick Ratio1.43
Debt / Equity11.66
Debt / EBITDA3.56
Interest Coverage18.39

Financial Efficiency

TWD

Over the twelve months ended September 30, 2026, Dabomb Protein Biotech Corporation posted a negative return on equity (ROE) of -2.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.09, reflecting losses generated across the asset base. The company generates approximately 8.02M in revenue per employee across its workforce of 47.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.97 indicates how many times Dabomb Protein Biotech Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.46
Return on Assets (ROA)-2.09
Revenue Per Employee8.02M
Employee Count47.00
Inventory Turnover9.97

Taxes

TWD

Over the twelve months ended September 30, 2026, Dabomb Protein Biotech Corporation recorded 6.53M in income tax expense. The company reported a pretax loss of -18.68M and -25.21M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax6.53M

Stock Price Statistics

TWD

As of the close on November 17, 2026, Dabomb Protein Biotech Corporation's stock has declined approximately 13.35% over the past 52 weeks. The 50-day moving average sits at 16.96, while the 200-day moving average is 17.33.

52-Week Price Change-13.35%
50-Day Moving Average16.96
200-Day Moving Average17.33

Income Statement

TWD

Over the twelve months ended September 30, 2026, Dabomb Protein Biotech Corporation generated 376.79M in revenue and converted that into -25.21M in net income, yielding earnings per share of -0.35. EBITDA reached 33.25M, while operating income came in at 4.42M.

Revenue376.79M
Gross Profit88.00M
Operating Income4.42M
Pretax Income-18.68M
Net Income-25.21M
EBITDA33.25M
EBIT4.42M
Earnings Per Share (EPS)-0.35

Balance Sheet

TWD

As of September 30, 2026, Dabomb Protein Biotech Corporation holds 221.35M in cash and equivalents against 118.35M in total debt, resulting in a net debt position of -83.53M. Total book value stands at 1.02B, with working capital of 158.82M providing operational flexibility.

Cash & Cash Equivalents221.35M
Total Debt118.35M
Net Debt-83.53M
Equity (Book Value)1.02B
Book Value Per Share14.11
Working Capital158.82M

Cash Flow

TWD

Dabomb Protein Biotech Corporation produced 31.69M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -13.94M in capital expenditures, free cash flow totaled 17.75M - equivalent to 0.25 per share.

Operating Cash Flow31.69M
Capital Expenditures-13.94M
Free Cash Flow17.75M
FCF Per Share0.25

Margins

Over the twelve months ended September 30, 2026, Dabomb Protein Biotech Corporation posted a gross margin of 23.36, reflecting its pricing power and cost economics. The operating margin of 1.17 and net profit margin of -6.69 provide insight into operational efficiency.

Gross Margin23.36
Operating Margin1.17
Pretax Margin-4.96
Profit Margin-6.69
EBITDA Margin8.82

Dividends & Yields

Over the twelve months ended September 30, 2026, Dabomb Protein Biotech Corporation paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dabomb Protein Biotech Corporation shareholders.

Shareholder Yield0.80
FCF Yield1.50

Stock Splits

Dabomb Protein Biotech Corporation's most recent stock split took place on December 1, 2021 with a 351:358 split ratio.

Last Split Date12/1/2021
Split Ratio351:358

Scores

As of September 30, 2026, Dabomb Protein Biotech Corporation has an Altman Z-Score of 4.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.85